...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Infectious Diseases >Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.
【24h】

Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.

机译：急性感染引发的高活性抗逆转录病毒治疗终止后，结合结构化治疗中断和基于免疫的治疗，可预测血浆人免疫缺陷病毒1型RNA的控制情况。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Thirty patients with acute human immunodeficiency virus (HIV) type 1 infection received a combination of 3 antiretroviral drugs (n=15) or 4 antiretroviral drugs plus hydroxyurea and interleukin-2 (n=15) for 24 months, followed by 1-3 structured therapeutic interruptions (STIs). Viral control, defined as maintaining plasma viremia <5000 copies/mL without therapy, was achieved in 14 cases. Lymphocyte subsets, plasma HIV-1 RNA loads, proviral DNA loads in peripheral blood mononuclear cells (PBMCs), residual HIV-1 RNA loads in PBMCs and in lymph node cells, and anti-p24 lymphoproliferative response were measured. In the multivariate analysis, proviral DNA loads in PBMCs and anti-p24 lymphoproliferative response assessed at 24 months were independently correlated with viral control after STI. These results enabled us to define a subgroup of patients for whom safe discontinuation of therapy initiated at acute infection was suitable and contributed to ascertaining priority for biological parameter assessment in future clinical trials.
机译：30例1型急性人类免疫缺陷病毒（HIV）感染患者接受了24个月的3种抗逆转录病毒药物（n = 15）或4种抗逆转录病毒药物加羟基脲和白介素2（n = 15）的组合，随后是1-3种结构化药物治疗中断（STIs）。在14例患者中实现了病毒控制，定义为无需治疗即可维持血浆病毒血症<5000拷贝/ mL。测量淋巴细胞亚群，血浆HIV-1 RNA负荷，外周血单核细胞（PBMC）中的原病毒DNA负荷，PBMC和淋巴结细胞中的残留HIV-1 RNA负荷以及抗p24淋巴组织增生反应。在多变量分析中，在STI后24个月评估的PBMC中的前病毒DNA负荷和抗p24淋巴组织增生反应与病毒控制独立相关。这些结果使我们能够确定亚组的患者，这些亚组适合于急性感染时安全终止治疗，并有助于确定在未来临床试验中进行生物学参数评估的优先级。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号